^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Iqirvo (elafibranor)

    i
    Other names: GFT505, GFT 505, GFT-505, IPN60190
    Associations

    News

    Trials
    Company:
    Genfit, Ipsen
    Drug class:
    PPAR α agonist, PPAR δ agonist
    Related drugs:
    Associations

    News

    Trials
    3d
    ELASCOPE: A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (clinicaltrials.gov)
    P3, N=350, Not yet recruiting, Ipsen
    New P3 trial
    |
    Iqirvo (elafibranor)
    5d
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial primary completion date
    |
    Iqirvo (elafibranor)
    2ms
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=69, Active, not recruiting, Ipsen | Trial completion date: Oct 2026 --> Jun 2026 | Trial primary completion date: Oct 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Iqirvo (elafibranor)
    9ms
    Compound 3d Attenuates Metabolic Dysfunction-Associated Steatohepatitis via Peroxisome Proliferator-Activated Receptor Pathway Activation and Inhibition of Inflammatory and Apoptotic Signaling. (PubMed, Metabolites)
    This study aimed to evaluate the therapeutic potential of compound 3d, a novel elafibranor derivative, focusing on its dual mechanisms of PPAR pathway activation and p38 MAPK signaling inhibition... Compound 3d alleviates MASH via PPAR-mediated lipid metabolism enhancement and p38 MAPK-driven inflammation/apoptosis suppression, with additional gut microbiota modulation. These findings highlight 3d as a multi-target therapeutic candidate for MASH.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ACOX1 (Acyl-CoA Oxidase 1)
    |
    Iqirvo (elafibranor)
    9ms
    ELSPIRE: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (clinicaltrials.gov)
    P3, N=69, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Iqirvo (elafibranor)
    11ms
    Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. (PubMed, World J Biol Chem)
    Future research should focus on elucidating EFN's molecular mechanisms and advancing its clinical application to establish its therapeutic potential in human populations. EFN represents a novel, comprehensive strategy for ALD management, targeting both liver and gut pathologies.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    Iqirvo (elafibranor)
    1year
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Recruiting, Ipsen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iqirvo (elafibranor)
    1year
    ELFINITY: A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment (clinicaltrials.gov)
    P=N/A, N=424, Recruiting, Ipsen | Trial completion date: Jul 2029 --> Jul 2032 | Trial primary completion date: Jul 2029 --> Jul 2032
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Iqirvo (elafibranor)
    1year
    ELONSEN: A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC) (clinicaltrials.gov)
    P3, N=18, Not yet recruiting, Ipsen
    New P3 trial
    |
    Iqirvo (elafibranor)
    1year
    Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. (PubMed, World J Gastroenterol)
    Additionally, alcohol disrupts the gut-liver axis at several interconnected levels, contributing to a proinflammatory environment in the liver. EFN helps alleviate intestinal hyperpermeability by restoring tight junction protein expression and autophagy, inhibiting apoptosis and inflammatory responses, and enhancing intestinal barrier function through PPARδ activation.
    Journal
    |
    PPARA (Peroxisome Proliferator Activated Receptor Alpha)
    |
    Iqirvo (elafibranor)
    over1year
    ELMWOOD: A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Ipsen | Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Dec 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Iqirvo (elafibranor)
    over1year
    ELFIDENCE: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis (clinicaltrials.gov)
    P3, N=276, Recruiting, Ipsen | Trial completion date: May 2030 --> May 2029
    Trial completion date
    |
    Iqirvo (elafibranor)